Delayed Gastric Conduit Emtpying (DGCE)WIDENCT07355374
Balloon Dilation in Patients Undergoing Minimally Invasive Ivor Lewis Esophagectomy and Its Effect on Reducing DGCE
A study testing endoscopic plyoric balloon dilatation performed by experienced gastroenterologists in people with Delayed Gastric Conduit Emtpying (DGCE) and Minimally-invasive Esophagectomy, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.
Trial summary
Background: Esophageal carcinoma ranks among the most common and lethal cancers worldwide. Minimally invasive esophagectomy is the standard curative treatment, but postoperative delayed gastric conduit emptying (DGCE) remains a major complication, occurring in up to 40% of patients. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Delayed Gastric Conduit Emtpying (DGCE), Minimally-invasive Esophagectomy
- What is being tested?
- endoscopic plyoric balloon dilatation performed by experienced gastroenterologists
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 116 participants
- Where
- 1 siteSwitzerland
- Study dates
- 15 Dec 2025to 1 Dec 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age >18 years
- Histologically confirmed esophageal cancer
- Planned surgical resection in curative intent as a minimally invasive Ivor Lewis procedure
- Provided informed consent
Who cannot join
- Prior esophageal or gastric resection
- Non-curative intent of surgery
- ASA Score V
- Patients lacking capacity to provide informed consent
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Switzerland1 site, 1 recruiting
- Recruiting
Clarunis University Digestive Health Care Center Basel
Basel, Canton of Basel-City, 4058
Lucien Cron, Resident, +41617777502, lucien.cron@clarunis.ch
Jennifer Klasen, PD. Dr. Med, +41617777513, jennifer.klasen@clarunis.ch
About this study
Official title: Patients With Esophageal Carcinoma Undergoing Minimally Invasive Ivor Lewis Esophagectomy With or Without Intraoperative Endoscopic Pylorus Balloon Dilation: A Randomized Controlled Trial Investigating the Benefits of Intraoperative Endoscopic Pylorus Dilation
Background:
Esophageal carcinoma ranks among the most common and lethal cancers worldwide. Minimally invasive esophagectomy is the standard curative treatment, but postoperative delayed gastric conduit emptying (DGCE) remains a major complication, occurring in up to 40% of patients. DGCE prolongs recovery, increases morbidity, and raises healthcare costs. Mechanical stretching of the pylorus has shown potential to reduce DGCE in retrospective studies, but evidence from randomized controlled trials in the context of minimally invasive surgery is lacking.
Read more
Objective:
The WIDE Trial aims to evaluate whether intraoperative endoscopic balloon dilation of the pylorus during minimally invasive Ivor-Lewis esophagectomy can reduce the incidence of early postoperative DGCE, improve recovery, and enhance quality of life.
Design:
This is a prospective, single-center, double-blinded, superiority randomized controlled trial conducted at Clarunis University Digestive Health Care Center, Basel. A total of 116 patients with histologically confirmed esophageal carcinoma undergoing minimally invasive esophagectomy with curative intent will be randomized 1:1 into an intervention group and a control group.
Intervention group: Intraoperative endoscopic balloon dilatation of the pylorus to 30 mm before gastric conduit formation.
Control group: Standard minimally invasive Ivor Lewis esophagectomy without dilatation.
Endpoints:
Primary endpoint: Incidence of early DGCE within 14 days postoperatively, defined by radiological and clinical criteria (gastric tube output >500 mL on day ≥5 or >100% increase in gastric tube width on X-ray).
Secondary endpoints: Late DGCE incidence (after >14 days), anastomotic leak rate, overall postoperative complications (Clavien-Dindo classification), hospital stay, time to first bowel movement, time to solid food intake, and postoperative quality of life (EORTC QLQ-OES18).
Methods and Follow-up:
Baseline data are collected preoperatively; postoperative outcomes are assessed at days 5, 10, and 3 months. Ward physicians and radiologists assessing outcomes are blinded to group assignment. At three months, all patients undergo follow-up including symptom questionnaires, radiological passage study, and QoL assessment.
Statistics:
Power analysis (α = 0.05, β = 0.20) based on prior studies suggests that 52 patients per group are needed to detect a reduction in DGCE incidence from 48% to 22%. Accounting for 10% attrition, 116 total patients will be enrolled. Analyses will follow the intention-to-treat principle using chi-square, t-tests/Mann-Whitney U tests, and multivariable logistic regression to adjust for confounders.
Risk-Benefit Assessment:
The intervention poses minimal additional risk, as balloon dilatation is an established and safe endoscopic procedure, adding approximately 20-30 minutes to surgical time. Possible complications such as perforation or bleeding are rare and manageable intraoperatively. Potential benefits include reduced DGCE incidence, shorter hospitalization, lower complication rates, and improved patient quality of life.
Ethics and Data Protection:
The study complies with the Declaration of Helsinki, ICH-GCP, and Swiss ClinO regulations (risk category A). All participants provide written informed consent. Patient data are pseudonymized and securely stored in a REDCap database.
Timeline:
Start of recruitment: December 2025
End of recruitment / last surgery: June 2028
Follow-up: 3 months per patient postoperatively
Expected Impact:
If intraoperative endoscopic pylorus dilatation proves effective, it could become a new standard adjunct procedure in minimally invasive esophagectomy, reducing DGCE-related morbidity and improving recovery and cost-efficiency in esophageal cancer surgery.
- Being tested
- endoscopic plyoric balloon dilatation performed by experienced gastroenterologists
- Keywords
- Balloon dilatation, intraoperatively, ivor lewis Esophagectomy, Delayed gastric conduit emtpying (DGCE)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
endoscopic plyoric balloon dilatation performed by experienced gastroenterologistsProcedure or surgery
Standard endoscopic plyoric balloon dilatation performed by experienced gastroenterologists as it would be performed to treat DGCE
| Study group | Role | What they receive |
|---|---|---|
| Dilation Group | Active comparator | Intervention group; patients receive additional dilation of the pylorus Receives: Procedure: endoscopic plyoric balloon dilatation performed by experienced gastroenterologists |
| Control | No intervention | In this group patients will undergo standard care without additional intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of Early Delayed Gastric Conduit Emptying (DGCE) on day 5 and 10
Early DGCE is defined as:
>500ml output of the nasogastric tube OR >100% increased gastric tube width on frontal X-Ray. If either one of the mentioned parameters is fullfilled DGCE is present. The Incidence of DGCE is our primary outcome and it is defined by one of the above mentioned criteria.
Measured: On postoperative day 5 and day 10 after the Intervention and the day of the esophagectomy.
Secondary outcomes (9)
Incidence of Late DGCE
After 3 months postoperatively (after the Intervention) patients are asked to fill out the DGCE symptom questionnaire and a radiological passage will be performed after 3 months to assess the passage of the contrast agent trough the GI-System.
Late DGCE is defined as: quite a bit or very much of at least 2 of 5 symptoms in the DGCE Quesitonniare and a verdict by the radiologist "delayed contrast passage".
Measured: Data will be collected 3 months after the intervention
Demographics
Demographical data: age, gender are collected for comparison of the results and potential confounders.
Measured: Demographic data will be collected prior to the Intervention on day X before the surgery in the surgical consultation, where patients provide the informed consent to participate in the study.
Weight
Body weight in kilograms at the time of the preoperative anesthesia consultation will be recorded
Measured: Baseline Day of the Intervention (Before the Intervention)
Perioperative parameters
Data concerning hospital and ICU stay (in days after Intervention) are collected for later analysis.
Measured: Data will be collected 3 months after the intervention
Past medical history
Past medical history are noted for comparison of the results and potential confounders.
Measured: Demographic data and past medical history will be collected prior to the Intervention on day X before the surgery in the surgical consultation, where patients provide the informed consent to participate in the study.
Rate of anastomotic leak
The anastomotic leak rate (diagnosed by endoscopy) will be recorded
Measured: Data will be collected 3 months after the intervention
Complication rate
All patients' complication rates will be recorded for comparison
Measured: Data will be collected 3 months after the intervention
First bowel movement
Time (in days) till first bowel movement after the operation is recorded
Measured: At discharge (assessed up to 5 days)
Postoperative quality of life
Postoperative quality of life will be assessed using the EORTC QLQ-OES18 questionnaire. Between 18 and 72 points can be reached. Higher scores indicate stronger symptoms and therefore lower quality of life
Measured: Data is collected 3 months after the intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Jan 2026
- Study start15 Dec 2025
- Primary completion31 Jul 2028 (estimated)
- Study completion1 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Delayed Gastric Conduit Emtpying (DGCE)Studies of the same condition, open and under way.
- More trials run by University Hospital, Basel, SwitzerlandThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 116 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Basel, Switzerland
- Sponsor type
- University, hospital or other
- Collaborators
- University Digestive Health Care Center Basel, Clarunis
- Responsible party
- Sponsor
- Investigators
- Beat Müller, Prof., Study director, Clarunis, University digestive health care centre basel
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07355374
- Sponsor's protocol ID
- 2025-01877
- Other IDs
- 2025
- Acronym
- WIDE
- Status last verified
- Mar 2026
- First submitted
- 14 Nov 2025
- Last updated
- 25 Mar 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: The data will be shared in an anonymized manner to protect participant privacy and prevent data breaches. Data sharing without pseudonymization is not permitted under Swiss ethical and regulatory requirements.
Publications
Boshier PR, Adam ME, Doran S, Muthuswamy K, Hanna GB. Effects of intraoperative pyloric stretch procedure on outcomes after esophagectomy. Dis Esophagus. 2018 Oct 1;31(10). doi: 10.1093/dote/doy038.
PubMed 29846516Nienhuser H, Heger P, Crnovrsanin N, Schaible A, Sisic L, Fuchs HF, Berlth F, Grimminger PP, Nickel F, Billeter AT, Probst P, Muller-Stich BP, Schmidt T. Mechanical stretching and chemical pyloroplasty to prevent delayed gastric emptying after esophageal cancer resection-a meta-analysis and review of the literature. Dis Esophagus. 2022 Jul 12;35(7):doac007. doi: 10.1093/dote/doac007.
PubMed 35178557Konradsson M, van Berge Henegouwen MI, Bruns C, Chaudry MA, Cheong E, Cuesta MA, Darling GE, Gisbertz SS, Griffin SM, Gutschow CA, van Hillegersberg R, Hofstetter W, Holscher AH, Kitagawa Y, van Lanschot JJB, Lindblad M, Ferri LE, Low DE, Luyer MDP, Ndegwa N, Mercer S, Moorthy K, Morse CR, Nafteux P, Nieuwehuijzen GAP, Pattyn P, Rosman C, Ruurda JP, Rasanen J, Schneider PM, Schroder W, Sgromo B, Van Veer H, Wijnhoven BPL, Nilsson M. Diagnostic criteria and symptom grading for delayed gastric conduit emptying after esophagectomy for cancer: international expert consensus based on a modified Delphi process. Dis Esophagus. 2020 Apr 15;33(4):doz074. doi: 10.1093/dote/doz074.
PubMed 31608938Cron L, Klasen JM, Neuschutz K, Dirnberger A, Maaser A, Baur J, Heinrich H, Gockel I, Bolli M, Muller BP, Kraljevic M. Intraoperative endoscopic pylorus dilatation during minimally invasive Ivor Lewis oesophagectomy to prevent delayed gastric conduit emptying (DGCE): protocol for the WIDE randomised controlled trial. BMJ Open. 2026 May 3;16(4):e117280. doi: 10.1136/bmjopen-2026-117280.
PubMed 42082244
Study at a glance
From the registry record, last updated by the sponsor on 25 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Patients With Esophageal Carcinoma Undergoing Minimally Invasive Ivor Lewis Esophagectomy With or Without Intraoperative Endoscopic Pylorus Balloon Dilation: A Randomized Controlled Trial Investigating the Benefits of Intraoperative Endoscopic Pylorus Dilation
- ClinicalTrials.gov ID
- NCT07355374
- Acronym / sponsor ID
- WIDE / 2025-01877
- Keywords
- Balloon dilatation, intraoperatively, ivor lewis Esophagectomy, Delayed gastric conduit emtpying (DGCE)
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 116 participants (estimated)
- Lead sponsor
- University Hospital, Basel, SwitzerlandUniversity, hospital or other
- Collaborators
- University Digestive Health Care Center Basel, Clarunis
- Study start
- 15 Dec 2025 (actual)
- Primary completion
- 31 Jul 2028 (estimated)
- Study completion
- 1 Dec 2028 (estimated)
- First posted
- 21 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background:
Esophageal carcinoma ranks among the most common and lethal cancers worldwide. Minimally invasive esophagectomy is the standard curative treatment, but postoperative delayed gastric conduit emptying (DGCE) remains a major complication, occurring in up to 40% of patients. DGCE prolongs recovery, increases morbidity, and raises healthcare costs. Mechanical stretching of the pylorus has shown potential to reduce DGCE in retrospective studies, but evidence from randomized controlled trials in the context of minimally invasive surgery is lacking.
Objective:
The WIDE Trial aims to evaluate whether intraoperative endoscopic balloon dilation of the pylorus during minimally invasive Ivor-Lewis esophagectomy can reduce the incidence of early postoperative DGCE, improve recovery, and enhance quality of life.
Design:
This is a prospective, single-center, double-blinded, superiority randomized controlled trial conducted at Clarunis University Digestive Health Care Center, Basel. A total of 116 patients with histologically confirmed esophageal carcinoma undergoing minimally invasive esophagectomy with curative intent will be randomized 1:1 into an intervention group and a control group.
Intervention group: Intraoperative endoscopic balloon dilatation of the pylorus to 30 mm before gastric conduit formation.
Control group: Standard minimally invasive Ivor Lewis esophagectomy without dilatation.
Endpoints:
Primary endpoint: Incidence of early DGCE within 14 days postoperatively, defined by radiological and clinical criteria (gastric tube output >500 mL on day ≥5 or >100% increase in gastric tube width on X-ray).
Secondary endpoints: Late DGCE incidence (after >14 days), anastomotic leak rate, overall postoperative complications (Clavien-Dindo classification), hospital stay, time to first bowel movement, time to solid food intake, and postoperative quality of life (EORTC QLQ-OES18).
Methods and Follow-up:
Baseline data are collected preoperatively; postoperative outcomes are assessed at days 5, 10, and 3 months. Ward physicians and radiologists assessing outcomes are blinded to group assignment. At three months, all patients undergo follow-up including symptom questionnaires, radiological passage study, and QoL assessment.
Statistics:
Power analysis (α = 0.05, β = 0.20) based on prior studies suggests that 52 patients per group are needed to detect a reduction in DGCE incidence from 48% to 22%. Accounting for 10% attrition, 116 total patients will be enrolled. Analyses will follow the intention-to-treat principle using chi-square, t-tests/Mann-Whitney U tests, and multivariable logistic regression to adjust for confounders.
Risk-Benefit Assessment:
The intervention poses minimal additional risk, as balloon dilatation is an established and safe endoscopic procedure, adding approximately 20-30 minutes to surgical time. Possible complications such as perforation or bleeding are rare and manageable intraoperatively. Potential benefits include reduced DGCE incidence, shorter hospitalization, lower complication rates, and improved patient quality of life.
Ethics and Data Protection:
The study complies with the Declaration of Helsinki, ICH-GCP, and Swiss ClinO regulations (risk category A). All participants provide written informed consent. Patient data are pseudonymized and securely stored in a REDCap database.
Timeline:
Start of recruitment: December 2025
End of recruitment / last surgery: June 2028
Follow-up: 3 months per patient postoperatively
Expected Impact:
If intraoperative endoscopic pylorus dilatation proves effective, it could become a new standard adjunct procedure in minimally invasive esophagectomy, reducing DGCE-related morbidity and improving recovery and cost-efficiency in esophageal cancer surgery.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Dilation Group | Active comparator | Procedure: endoscopic plyoric balloon dilatation performed by experienced gastroenterologistsIntervention group; patients receive additional dilation of the pylorus |
| Control | No intervention | –In this group patients will undergo standard care without additional intervention |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Age >18 years
- Histologically confirmed esophageal cancer
- Planned surgical resection in curative intent as a minimally invasive Ivor Lewis procedure
- Provided informed consent
Key exclusion criteria (4 listed)
- Prior esophageal or gastric resection
- Non-curative intent of surgery
- ASA Score V
- Patients lacking capacity to provide informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| endoscopic plyoric balloon dilatation performed by experienced gastroenterologistsStandard endoscopic plyoric balloon dilatation performed by experienced gastroenterologists as it would be performed to treat DGCE | Procedure or surgery | Dilation Group |
Primary outcome
Incidence of Early Delayed Gastric Conduit Emptying (DGCE) on day 5 and 10
Time frame: On postoperative day 5 and day 10 after the Intervention and the day of the esophagectomy.
Early DGCE is defined as: >500ml output of the nasogastric tube OR >100% increased gastric tube width on frontal X-Ray. If either one of the mentioned parameters is fullfilled DGCE is present. The Incidence of DGCE is our primary outcome and it is defined by one of the above mentioned criteria.
9 secondary outcomes
Incidence of Late DGCE
Time frame: Data will be collected 3 months after the intervention
Demographics
Time frame: Demographic data will be collected prior to the Intervention on day X before the surgery in the surgical consultation, where patients provide the informed consent to participate in the study.
Weight
Time frame: Baseline Day of the Intervention (Before the Intervention)
Perioperative parameters
Time frame: Data will be collected 3 months after the intervention
Past medical history
Time frame: Demographic data and past medical history will be collected prior to the Intervention on day X before the surgery in the surgical consultation, where patients provide the informed consent to participate in the study.
Rate of anastomotic leak
Time frame: Data will be collected 3 months after the intervention
Complication rate
Time frame: Data will be collected 3 months after the intervention
First bowel movement
Time frame: At discharge (assessed up to 5 days)
Postoperative quality of life
Time frame: Data is collected 3 months after the intervention
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Mar 2026.
- Background: PubMed 29846516Boshier PR, Adam ME, Doran S, Muthuswamy K, Hanna GB. Effects of intraoperative pyloric stretch procedure on outcomes after esophagectomy. Dis Esophagus. 2018 Oct 1;31(10). doi: 10.1093/dote/doy038.
- Background: PubMed 35178557Nienhuser H, Heger P, Crnovrsanin N, Schaible A, Sisic L, Fuchs HF, Berlth F, Grimminger PP, Nickel F, Billeter AT, Probst P, Muller-Stich BP, Schmidt T. Mechanical stretching and chemical pyloroplasty to prevent delayed gastric emptying after esophageal cancer resection-a meta-analysis and review of the literature. Dis Esophagus. 2022 Jul 12;35(7):doac007. doi: 10.1093/dote/doac007.
- Background: PubMed 31608938Konradsson M, van Berge Henegouwen MI, Bruns C, Chaudry MA, Cheong E, Cuesta MA, Darling GE, Gisbertz SS, Griffin SM, Gutschow CA, van Hillegersberg R, Hofstetter W, Holscher AH, Kitagawa Y, van Lanschot JJB, Lindblad M, Ferri LE, Low DE, Luyer MDP, Ndegwa N, Mercer S, Moorthy K, Morse CR, Nafteux P, Nieuwehuijzen GAP, Pattyn P, Rosman C, Ruurda JP, Rasanen J, Schneider PM, Schroder W, Sgromo B, Van Veer H, Wijnhoven BPL, Nilsson M. Diagnostic criteria and symptom grading for delayed gastric conduit emptying after esophagectomy for cancer: international expert consensus based on a modified Delphi process. Dis Esophagus. 2020 Apr 15;33(4):doz074. doi: 10.1093/dote/doz074.
- Derived from this study: PubMed 42082244Cron L, Klasen JM, Neuschutz K, Dirnberger A, Maaser A, Baur J, Heinrich H, Gockel I, Bolli M, Muller BP, Kraljevic M. Intraoperative endoscopic pylorus dilatation during minimally invasive Ivor Lewis oesophagectomy to prevent delayed gastric conduit emptying (DGCE): protocol for the WIDE randomised controlled trial. BMJ Open. 2026 May 3;16(4):e117280. doi: 10.1136/bmjopen-2026-117280.
- Individual participant dataSharing planned: Undecided. The data will be shared in an anonymized manner to protect participant privacy and prevent data breaches. Data sharing without pseudonymization is not permitted under Swiss ethical and regulatory requirements.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Beat Müller, Prof. study director
Clarunis, University digestive health care centre basel
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing endoscopic plyoric balloon dilatation performed by experienced gastroenterologists in people with Delayed Gastric Conduit Emtpying (DGCE) and Minimally-invasive Esophagectomy, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 25 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Lucien Cron, cand. med (061 777 75 02 ext. +41, lucien.cron@clarunis.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of Early Delayed Gastric Conduit Emptying (DGCE) on day 5 and 10 (time frame: On postoperative day 5 and day 10 after the Intervention and the day of the esophagectomy.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07355374, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Mar 2026.